Preclinical models for acquired resistance to third-generation egfr inhibitors in nsclc: functional studies and drug combinations used to overcome resistance

HIGHLIGHTS

• who: Emna Mahfoudhi from the Universitaire de Rennes, Service de Pneumologie, Universitu00e9 de Rennes, Rennes, France University of Pisa, Italy have published the paper: Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance, in the Journal: (JOURNAL)

SUMMARY

Epidermal growth factor receptor (EGFR)-activating mutations in non-small-cell lung cancer (NSCLC) are an important predictor of treatment efficacy with EGFR tyrosine kinase inhibitors (TKIs). EGFR-TKIs have been shown to prolong the survival of patients with tumors harboring EGFR-activating . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.